{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:45:35Z","timestamp":1794091535225,"version":"4.8.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most debilitating long-term side effects in breast cancer survivors. We conducted a randomized controlled pilot trial to assess the feasibility, safety, and effects of an acupuncture intervention on CIPN in this population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>Women with stage I\u2013III breast cancer with grade 1 or higher CIPN after taxane-containing adjuvant chemotherapy were randomized 1:1 to an immediate acupuncture (IA) arm or to a waitlist control group (CG). Participants in the IA arm received 18 sessions of acupuncture over 8\u2009weeks, then received no additional acupuncture. Patients in the CG arm received usual care over 8\u2009weeks, followed by nine sessions of acupuncture over 8\u2009weeks. Measures including Patient Neurotoxicity Questionnaire (PNQ), Functional Assessment of Cancer Therapy\u2014Neurotoxicity subscale (FACT-NTX), and Brief Pain Inventory\u2014short form (BPI-SF) were collected at baseline and at 4, 8, and 16\u2009weeks after enrollment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty women (median age, 54) were enrolled (20 to IA and 20 to CG), with median time between completion of chemotherapy and enrollment of 14 months (range 1\u201392). At 8\u2009weeks, participants in the IA arm experienced significant improvements in PNQ sensory score (\u22121.0 \u00b1\u20090.9 vs. \u22120.3 \u00b1\u20090.6; p = .01), FACT-NTX summary score (8.7 \u00b1\u20098.9 vs. 1.2 \u00b1\u20095.4; p = .002), and BPI-SF pain severity score (\u22121.1 \u00b1\u20091.7 vs. 0.3 \u00b1\u20091.5; p = .03), compared with those in the CG arm. No serious side effects were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Women with CIPN after adjuvant taxane therapy for breast cancer experienced significant improvements in neuropathic symptoms from an 8-week acupuncture treatment regimen. Additional larger studies are needed to confirm these findings.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0489","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T18:45:14Z","timestamp":1571078714000},"page":"310-318","source":"Crossref","is-referenced-by-count":161,"title":["Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial"],"prefix":"10.1093","volume":"25","author":[{"given":"Weidong","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Giobbie-Hurder","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Freedman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Im Hee","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics and Informatics, School of Medicine at the Catholic University of Daegu, Daegu, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann H.","family":"Partridge","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Ligibel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,14]]},"reference":[{"key":"2021122510222664500_R1","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"2021122510222664500_R2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","article-title":"Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: Prevalence, risk factors","volume":"159","author":"Bao","year":"2016","journal-title":"and fall risk. Breast Cancer Res Treat"},{"key":"2021122510222664500_R3","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s11136-017-1635-0","article-title":"The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice","volume":"26","author":"Simon","year":"2017","journal-title":"Qual Life Res"},{"key":"2021122510222664500_R4","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx162","article-title":"Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG oncology\/NSABP B-30","volume":"110","author":"Bandos","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2021122510222664500_R5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s10147-011-0352-x","article-title":"Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer","volume":"18","author":"Tanabe","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"2021122510222664500_R6","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2016.71.3552","article-title":"Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy","volume":"35","author":"Winters-Stone","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122510222664500_R7","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jamaneurol.2016.0383","article-title":"The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling","volume":"73","author":"Kolb","year":"2016","journal-title":"JAMA Neurol"},{"key":"2021122510222664500_R8","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122510222664500_R9","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1200\/JCO.2005.06.028","article-title":"Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting","volume":"23","author":"Ezzo","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122510222664500_R10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jama.2018.8907","article-title":"Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: A randomized clinical trial","volume":"320","author":"Hershman","year":"2018","journal-title":"JAMA"},{"key":"2021122510222664500_R11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.06.008","article-title":"A phase IIa trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients","volume":"101","author":"Bao","year":"2018","journal-title":"Eur J Cancer"},{"key":"2021122510222664500_R12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1756-8722-7-41","article-title":"Electroacupuncture for thalidomide\/bortezomib-induced peripheral neuropathy in multiple myeloma: A feasibility study","volume":"7","author":"Garcia","year":"2014","journal-title":"J Hematol Oncol"},{"key":"2021122510222664500_R13","first-page":"18","article-title":"A randomized assessor-blinded wait-list-controlled trial to assess the effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy","author":"Molassiotis","year":"2019","journal-title":"Integr Cancer Ther"},{"key":"2021122510222664500_R14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12885-016-3037-z","article-title":"Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma","volume":"17","author":"Han","year":"2017","journal-title":"BMC Cancer"},{"key":"2021122510222664500_R15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/107555302753507212","article-title":"Standards for reporting interventions in controlled trials of acupuncture: The STRICTA recommendations","volume":"8","author":"MacPherson","year":"2002","journal-title":"J Altern Complement Med"},{"key":"2021122510222664500_R16","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00520-009-0613-7","article-title":"Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02","volume":"17","author":"Shimozuma","year":"2009","journal-title":"Support Care Cancer"},{"key":"2021122510222664500_R17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","article-title":"Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy","volume":"33","author":"Hausheer","year":"2006","journal-title":"Semin Oncol"},{"key":"2021122510222664500_R18","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1007\/s00520-012-1492-x","article-title":"Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02","volume":"20","author":"Shimozuma","year":"2012","journal-title":"a randomized clinical trial. Support Care Cancer"},{"key":"2021122510222664500_R19","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1007\/s00520-017-3772-y","article-title":"Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): A systematic review and delphi survey","volume":"25","author":"McCrary","year":"2017","journal-title":"Support Care Cancer"},{"key":"2021122510222664500_R20","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00520-008-0550-x","article-title":"Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study)","volume":"17","author":"Kuroi","year":"2009","journal-title":"Support Care Cancer"},{"key":"2021122510222664500_R21","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cncr.11578","article-title":"Measuring the side effects of taxane therapy in oncology: The Functional Assesment of Cancer Therapy-Taxane (FACT-Taxane)","volume":"98","author":"Cella","year":"2003","journal-title":"Cancer"},{"key":"2021122510222664500_R22","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"2021122510222664500_R23","first-page":"129","article-title":"Pain assessment: Global use of the brief pain inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singapore"},{"key":"2021122510222664500_R24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2021122510222664500_R25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00451727","article-title":"Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast","volume":"3","author":"Osoba","year":"1994","journal-title":"ovarian and lung cancer. Qual Life Res"},{"key":"2021122510222664500_R26","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.ejca.2008.05.008","article-title":"Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials","volume":"44","author":"Cocks","year":"2008","journal-title":"Eur J Cancer"},{"key":"2021122510222664500_R27","first-page":"457","article-title":"Clinical randomized controlled study on acupuncture for treatment of peripheral neuropathy induced by chemotherapeutic drugs [in Chinese]","volume":"30","author":"Xu","year":"2010","journal-title":"Zhongguo Zhen Jiu"},{"key":"2021122510222664500_R28","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"key":"2021122510222664500_R29","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s00520-013-1731-9","article-title":"Minimal clinically important differences in the brief pain inventory in patients with bone metastases","volume":"21","author":"Wong","year":"2013","journal-title":"Support Care Cancer"},{"key":"2021122510222664500_R30","doi-asserted-by":"crossref","DOI":"10.3747\/co.26.4261","article-title":"A systematic review of acupuncture for chemotherapy-induced peripheral neuropathy","volume":"26","author":"Li","year":"2019","journal-title":"Curr Oncol"},{"key":"2021122510222664500_R31","doi-asserted-by":"crossref","first-page":"516916","DOI":"10.1155\/2013\/516916","article-title":"A systematic review of experimental and clinical acupuncture in chemotherapy-induced peripheral neuropathy","volume":"2013","author":"Franconi","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"2021122510222664500_R32","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1212\/WNL.0000000000004272","article-title":"Chemotherapy-induced peripheral neuropathy clinical trials: Review and recommendations","volume":"89","author":"Gewandter","year":"2017","journal-title":"Neurology"},{"key":"2021122510222664500_R33","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"2021122510222664500_R34","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00520-015-3063-4","article-title":"National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: Outcomes and lessons","volume":"24","author":"Majithia","year":"2016","journal-title":"Support Care Cancer"},{"key":"2021122510222664500_R35","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1188\/07.CJON.901-913","article-title":"Putting evidence into practice: Evidence-based interventions for chemotherapy-induced peripheral neuropathy","volume":"11","author":"Visovsky","year":"2007","journal-title":"Clin J Oncol Nurs"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0489","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0489","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/4\/310\/41919218\/oncolo_25_4_310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/4\/310\/41919218\/oncolo_25_4_310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:23:03Z","timestamp":1640427783000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/4\/310\/6443385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,14]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,10,14]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0489","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4,1]]},"published":{"date-parts":[[2019,10,14]]}}}